# **Fulfilling the Sawai Group Corporate Philosophy**

# Dedicated to building a healthier future for all

Sawai Group corporate philosophy

The Sawai Group corporate philosophy of "dedicated to building a healthier future for all" embodies our desire to contribute to the health of as many people as possible as a healthcare corporate group which develops sustainably alongside society, with the generic drugs business as our core business. We will mobilize the strengths of all Group employees to pursue the challenge of meeting the expectations of all stakeholders.

#### Sawai Group Mind



The Sawai Group will serve every stakeholder wholeheartedly.

The Sawai Group will continue the challenge to improve access to healthcare for more people.

The Sawai Group aspires to play a pivotal role in healthcare through its contribution to society.

#### Contents

### 5 | Management message

- 5 Message from the CEO
- 11 Medium-term Business Plan "Bevond 2027"

#### Our value creation story

- 13 Our value creation model
- 15 Sustainability at the Sawai Group

### Value creation strategy

- 19 Generic drugs market landscape
- 21 Japan generic drug business
- 25 New husinesses
- 27 Message from the CFO
- 29 Research & development
- 31 Intellectual property
- 33 Growing production capacity
- 35 Human capital strategy
- 39 Society
- 41 Environment

# Governance

- 43 Dialogue with investors and directors
- 47 Board of Directors
- 49 Corporate governance

# Eleven-year financial and non-financial



### **Editorial policy**

This report references the International Financial Reporting Standards Foundation's International Integrated Report Framework and includes information that could impact our mediumto long-term corporate value creation and that is connected with information about the Company's strategies, performance, and future projections, as well as non-financial information concerning the environment, society, and governance. The contents herein have been assigned priority internally based on their nature and quantity, risks, opportunities, and dialogues with stakeholders, and have been deemed to be of particular importance.

This report has been prepared by the Group Sustainability Committee, which is supervised by the President, and with the support of the committee's administrative office.

# Reporting period: April 1, 2024 to March 31, 2025

# Abbreviations used:

In this report, "generic drugs" are abbreviated as either "GE drugs" or "GE."

### A caution concerning forward-looking statements:


This report contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at the time of publication. Accordingly, please be aware that the impact of certain risks and uncertainties could cause the Company's actual results to differ materially from any projections

# **Group history**

Not only "always putting patients first" but also striving to succeed in

"dedicated to building a healthier future" for all people





1929-

1930

1929

Sawai Pharmacy, the predecessor

of Sawai Pharmaceutical Co., Ltd.,

1940

was founded in Asahi-ku,

# Sawai Pharmacy founded in Asahi-ku Osaka as local pharmacy

Sawai Pharmaceutical's history starts almost 100 years ago. Hanpei Sawai and Noyo Sawai (a pharmacist) established Sawai Pharmacy, Sawai Pharmaceutical's predecessor. At that time, there were few pharmacies, and Sawai Pharmacy supported the health of residents by providing drugs as a local pharmacy.

1965-

1970

1965

Sawai Pharmaceutical Co., Ltd.

was incorporated in Asahi-ku,

1960

Osaka City.

1950

Shifted from making OTC drugs

to ethical pharmaceuticals.

# Transformed into manufacturer of prescription medications and then into a leading GE company

1980

1990

In response to changes in the drug market due to the introduction of a universal medical care insurance system, Sawai transformed itself from a manufacturer of over-the-counter medications into a manufacturer of prescription medications. By supplying one product after another that meet the needs of healthcare professionals, we have built a foundation to grow into a leading company in the generic drug industry.

2003-

# Contributed to spreading and expanding GE as a company listed on the First Section of the Tokyo Stock Exchange

In line with the basic policies of expanding market share, further strengthening the management structure, and building a solid Sawai brand, Sawai continued to grow, boosted by the tail wind of government policies to promote the use of generic drugs. We also strengthened our production and development capabilities, which included construction of the Kanto and Sanda Nishi factories and a new development center.

2021-

# Transformed into GE manufacturer that continues to be selected with an eye toward industry reorganization

Sawai transitioned to a holding company structure in 2021 in order to strengthen its existing businesses and foster new businesses, as well as to strengthen the governance function that supports both. As a part of the social infrastructure, we will strive to ensure a stable supply of inexpensive, high-quality generic drugs while further enhancing our industry-leading production capacity and sales volume.

Sawai Group Holdings Integrated Report 2025